1: Bogen A, Buske C, Hiddemann W, Bohlander SK, Christ O. Variable aldehyde

dehydrogenase activity and effects on chemosensitivity of primitive human

leukemic cells. Exp Hematol. 2016 Nov 5. pii: S0301-472X(16)30695-6. doi:

10.1016/j.exphem.2016.10.012. [Epub ahead of print] PubMed PMID: 27826122.


2: Pastore F, Schneider S, Christ O, Hiddemann W, Spiekermann K. Impressive

thrombocytosis evolving in a patient with a BCR-ABL positive CML in major

molecular response during dasatinib treatment unmasks an additional JAK2V617F.

Exp Hematol Oncol. 2013 Sep 5;2(1):24.


3: Weigert O, Wittmann G, Grützner S, Christ O, Christ B, Rank A, Ostermann H.

Vincristine-loaded platelets for immune thrombocytopenia. Thromb Haemost. 2010



4: Christ O, Lucke K, Imren S, Leung K, Hamilton M, Eaves A, Smith C, Eaves C.

Improved purification of hematopoietic stem cells based on their elevated

aldehyde dehydrogenase activity. Haematologica. 2007 Sep;92(9):1165-72.


5: Christ O, Feuring-Buske M, Hiddemann W, Buske C. [Pathobiology of acute

myeloid leukemia]. Med Klin (Munich). 2007 Apr 15;102(4):290-5. Review. German.


6: Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E, Lambie K, Shaw G,

Holyoake TL, Petzer AL, Auewarakul C, Barnett MJ, Eaves CJ, Eaves AC. Different

subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient

mice and produce a model of the human disease. Leukemia. 2005 Mar;19(3):435-41.



7: Chalandon Y, Jiang X, Christ O, Loutet S, Thanopoulou E, Eaves A, Eaves C.

BCR-ABL-transduced human cord blood cells produce abnormal populations in

immunodeficient mice. Leukemia. 2005 Mar;19(3):442-8. 


8: Christ O, Günthert U, Schmidt DS, Zöller M. Allogeneic reconstitution after

nonmyeloablative conditioning: mitigation of graft-versus-host and

host-versus-graft reactivity by anti-CD44v6. J Leukoc Biol. 2002 Jan;71(1):33-46.


9: Weth R, Christ O, Stevanovic S, Zöller M. Gene delivery by attenuated

Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell 

priming in tumor vaccination. Cancer Gene Ther. 2001 Aug;8(8):599-611.


10: Christ O, Matzku S, Burger C, Zöller M. Interleukin 2-antibody and tumor

necrosis factor-antibody fusion proteins induce different antitumor immune

responses in vivo. Clin Cancer Res. 2001 May;7(5):1385-97. 


11: Christ O, Seiter S, Matzku S, Burger C, Zöller M. Efficacy of local versus

systemic application of antibody-cytokine fusion proteins in tumor therapy. Clin 

Cancer Res. 2001 Apr;7(4):985-98. 


12: Christ O, Kronenwett R, Haas R, Zöller M. Combining G-CSF with a blockade of 

adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic

progenitor cells. Exp Hematol. 2001 Mar;29(3):380-90. 


13: Christ O, Günthert U, Haas R, Zöller M. Importance of CD44v7 isoforms for

homing and seeding of hematopoietic progenitor cells. J Leukoc Biol. 2001



14: Banat GA, Christ O, Cochlovius B, Pralle HB, Zöller M. Tumour-induced

suppression of immune response and its correction. Cancer Immunol Immunother.

2001 Jan;49(11):573-86.


15: Zöller M, Christ O. Prophylactic tumor vaccination: comparison of effector

mechanisms initiated by protein versus DNA vaccination. J Immunol. 2001 Mar



16: Cochlovius B, Stassar M, Christ O, Raddrizzani L, Hammer J, Mytilineos I,

Zöller M. In vitro and in vivo induction of a Th cell response toward peptides of

the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE

program. J Immunol. 2000 Oct 15;165(8):4731-41. 


17: Cochlovius B, Kipriyanov SM, Stassar MJ, Christ O, Schuhmacher J, Strauss G, 

Moldenhauer G, Little M. Treatment of human B cell lymphoma xenografts with a CD3

x CD19 diabody and T cells. J Immunol. 2000 Jul 15;165(2):888-95.